Characterization of Patients With Difficult-to-Control Type 2 Diabetes and a Post–Dexamethasone Suppression Test Cortisol of 1.2–1.8 μg/dL: Findings From a Large Prospective Study

Summary  

  • Data collected in CATALYST allowed us to explore characteristics associated with different post-DST cortisol values and to better understand the impact of different post-DST cortisol levels on comorbidities
  • The results of this analysis suggest that there is a continuum of cardiometabolic risk as a function of nonsuppressible cortisol
  • As this analysis showed, individuals with post-DST cortisol 1.2–1.8 μg/dL share similarities in clinical characteristics with those who have DST results above the current hypercortisolism diagnostic cutoff, suggesting that further investigation of this group may be warranted


Download PDF

© 2025 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube